 PATIENT POPULATION: Patients with relapsed or refractory multiple myeloma requiring therapy will be invited to participate in this study. Eligible patients will be 18 years old and able to give fully informed consent. Patients must have a Performance Score PS of 0-3 ECOG, measurable serum andor urine paraprotein, or serum free light chain, bilirubin value of less than one and a half times the upper limit of normal with ALTAST values less than two and a half times the upper limit of normal. Patients with non-secretory multiple myeloma are excluded from this study. 